Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin
- 28 June 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 61 (5-6), 341-346
- https://doi.org/10.1007/s00228-005-0907-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 ActivityThe Journal of Clinical Pharmacology, 2004
- THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGSDrug Metabolism and Disposition, 2004
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probeClinical Pharmacology & Therapeutics, 2003
- Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisoloneClinical Pharmacology & Therapeutics, 2003
- Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone AloneJournal of Clinical Oncology, 2001
- Clinically Important Drug Interactions with AnticoagulantsClinical Pharmacokinetics, 1996
- Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic modelClinical Pharmacology & Therapeutics, 1994
- Method for studying drug-warfarin interactionsClinical Pharmacology & Therapeutics, 1993
- Oral Anticoagulant DrugsNew England Journal of Medicine, 1991